Cellectar Biosciences (NVLT) Announces Receipt Of Orphan Designation Of I-124-CLR1404 As Diagnostic For The Management Of Glioma From FDA
5/5/2014 9:33:38 AM
MADISON, Wis., May 5, 2014 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (OTCQX:CLRB), a clinical stage biopharmaceutical company developing innovative agents for the detection and treatment of cancer, announced that it has received notification from the U.S. Food and Drug Administration (FDA) granting Cellectar's request for orphan drug designation for I-124-CLR1404 as a diagnostic for the management of glioma, the most common and aggressive form of brain cancer.
Help employers find you! Check out all the jobs and post your resume.
comments powered by